Failure of atropine to inhibit gastrin-17 stimulation of the lower esophageal sphincter in man.
Heptadecapeptide gastrin I (G-17) contrast the lower esophageal sphincter (LES) in man and animals. Previous studies in man found that atropine infusion (12 microgram kg-1hr-1) inhibited the effect of gastrin on the LES, suggesting that this effect of gastrin is mediated by a cholinergic mechanism. Studies in the opossum have not shown similar inhibition. To reevaluate the interaction of atropine and G-17 on the LES, 5 normal males were studied. Submaximal and maximal effective doses of G-17 were used with both atropine infusion (12 microgram kg-1hr-1) and rapid intravenous injection (1 mg). There was a small decrease in basal LES pressure with atropine infusion. However, neither atropine infusion nor rapid intravenous injection inhibited LES stimulation by submaximal and maximal doses of G-17. The results do not support the hypothesis that LES responses to gastrin are mediated by an atropine-sensitive cholinergic mechanism.
D000328:Adult; D001285:Atropine / Q000008:administration & dosage / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004943:Esophagogastric Junction / Q000187:drug effects*; D005755:Gastrins / Q000494:pharmacology*; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010275:Parasympathetic Nervous System / Q000502:physiology; D011312:Pressure; D013268:Stimulation, Chemical
D005755:Gastrins; D001285:Atropine